Immunotherapy for metastatic colorectal cancer: Present status and new options.
Jan 2012 - :1502-7708 [PMID:22214467]
[Ellebaek E] [Andersen MH] [Svane IM] [Straten PT]

Changes in peripheral blood level of regulatory T cells in malignant melanoma patients during treatment with dendritic cell vaccination and low dose IL-2.
Jan 2011 - :1365-3083 [PMID:21204893]
[Bjoern J] [Brimnes MK] [Andersen MH] [Thor Straten P] [Svane IM]

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Apr 2010 - :1477-2566 [PMID:20429791]
[Trepiakas R] [Berntsen A] [Hadrup SR] [Bjørn J] [Geertsen PF] [Straten PT] [Andersen MH] [Pedersen AE] [Soleimani A] [Lorentzen T] [Johansen JS] [Svane IM]

Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Apr 2010 - J. Immunother.; 33(4):1537-4513 [PMID:20386464]
[Berntsen A] [Brimnes MK] [thor Straten P] [Svane IM]

Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Okt 2009 - Scand. J. Immunol.; 70(5):1365-3083 [PMID:19874553]
[Soleimani A] [Berntsen A] [Svane IM] [Pedersen AE]

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.
Okt 2008 - Cancer Immunol. Immunother.; 58(1):1432-0851 [PMID:18719915]
[Engell-Noerregaard L] [Hansen TH] [Andersen MH] [Thor Straten P] [Svane IM]

Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
Sep 2008 - J. Immunother.; 31(8):1537-4513 [PMID:18779742]
[Berntsen A] [Trepiakas R] [Wenandy L] [Geertsen PF] [thor Straten P] [Andersen MH] [Pedersen AE] [Claesson MH] [Lorentzen T] [Johansen JS] [Svane IM]

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Aug 2008 - Vaccine; 26(36):0264-410X [PMID:18616968]
[Svane IM] [Pedersen AE] [Nikolajsen K] [Zocca MB]

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Jun 2007 - Cancer Immunol. Immunother.; 56(9):0340-7004 [PMID:17285289]
[Svane IM] [Pedersen AE] [Johansen JS] [Johnsen HE] [Nielsen D] [Kamby C] [Ottesen S] [Balslev E] [Gaarsdal E] [Nikolajsen K] [Claesson MH]

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Jun 2006 - Eur. Urol.; 50(1):0302-2838 [PMID:16675096]
[Berntsen A] [Geertsen PF] [Svane IM]

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
Jun 2004 - Cancer Immunol. Immunother.; 53(7):0340-7004 [PMID:14985857]
[Svane IM] [Pedersen AE] [Johnsen HE] [Nielsen D] [Kamby C] [Gaarsdal E] [Nikolajsen K] [Buus S] [Claesson MH]